Cargando…

Primary Cardiac Angiosarcoma

Primary cardiac sarcoma is a rare clinical entity, with an incidence of 0.0001% in collected autopsy series. The majority of the literature describes a uniformly dismal prognosis with a median survival of only 6 months for these aggressive tumors. Standard surgery, adjuvant chemotherapy, and radioth...

Descripción completa

Detalles Bibliográficos
Autores principales: Kodali, Dhatri, Seetharaman, Kala
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1698140/
https://www.ncbi.nlm.nih.gov/pubmed/17251657
http://dx.doi.org/10.1155/SRCM/2006/39130
_version_ 1782131226623082496
author Kodali, Dhatri
Seetharaman, Kala
author_facet Kodali, Dhatri
Seetharaman, Kala
author_sort Kodali, Dhatri
collection PubMed
description Primary cardiac sarcoma is a rare clinical entity, with an incidence of 0.0001% in collected autopsy series. The majority of the literature describes a uniformly dismal prognosis with a median survival of only 6 months for these aggressive tumors. Standard surgery, adjuvant chemotherapy, and radiotherapy have been consistently unsuccessful. Early heart transplantation and novel radiation therapy approaches may offer a survival benefit in nonmetastatic tumors, but up to 80% of the patients present with systemic metastasis at diagnosis. Though several chemotherapeutic regimens have been tried, the role of chemotherapy is not well established and outcome data available is minimal. Liposomal doxorubicin (PLD) has been shown to be useful in the treatment of soft tissue sarcomas, and our case supports its use in cardiac angiosarcoma.
format Text
id pubmed-1698140
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-16981402007-01-17 Primary Cardiac Angiosarcoma Kodali, Dhatri Seetharaman, Kala Sarcoma Case Report Primary cardiac sarcoma is a rare clinical entity, with an incidence of 0.0001% in collected autopsy series. The majority of the literature describes a uniformly dismal prognosis with a median survival of only 6 months for these aggressive tumors. Standard surgery, adjuvant chemotherapy, and radiotherapy have been consistently unsuccessful. Early heart transplantation and novel radiation therapy approaches may offer a survival benefit in nonmetastatic tumors, but up to 80% of the patients present with systemic metastasis at diagnosis. Though several chemotherapeutic regimens have been tried, the role of chemotherapy is not well established and outcome data available is minimal. Liposomal doxorubicin (PLD) has been shown to be useful in the treatment of soft tissue sarcomas, and our case supports its use in cardiac angiosarcoma. Hindawi Publishing Corporation 2006 2006-10-04 /pmc/articles/PMC1698140/ /pubmed/17251657 http://dx.doi.org/10.1155/SRCM/2006/39130 Text en Copyright © 2006 D. Kodali and K. Seetharaman. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Kodali, Dhatri
Seetharaman, Kala
Primary Cardiac Angiosarcoma
title Primary Cardiac Angiosarcoma
title_full Primary Cardiac Angiosarcoma
title_fullStr Primary Cardiac Angiosarcoma
title_full_unstemmed Primary Cardiac Angiosarcoma
title_short Primary Cardiac Angiosarcoma
title_sort primary cardiac angiosarcoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1698140/
https://www.ncbi.nlm.nih.gov/pubmed/17251657
http://dx.doi.org/10.1155/SRCM/2006/39130
work_keys_str_mv AT kodalidhatri primarycardiacangiosarcoma
AT seetharamankala primarycardiacangiosarcoma